SCHEMBL6476013

SCHEMBL6476013

COC(=O)C(Cc1ccc(OCCn2c(=O)oc3cc(Cc4ccccc4)ccc32)cc1)C(=O)OC

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.56
PPARA Q07869 4/20 0.50
PPARD Q03181 4/20 0.50
SIGMAR1 Q99720 1/20 0.49
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 4/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476311 0.92 SIGMAR1 (0.53) PPARGPPARAPPARDSIGMAR1RAB9A
SCHEMBL6483665 0.88 PPARG (0.70) PPARGPPARAPPARDSIGMAR1RAB9A
SCHEMBL6485878 0.87 PPARG (0.53) PPARGPPARAPPARDRAB9AALDH1A1
SCHEMBL6477333 0.82 PPARG (0.78) PPARGPPARAPPARDRAB9AALDH1A1
SCHEMBL6477400 0.79 TSHR (0.62) PPARGPPARAPPARDRAB9AALDH1A1
SCHEMBL6476791 0.79 L3MBTL1 (0.58) PPARGPPARAPPARDRAB9AALDH1A1
SCHEMBL6477277 0.79 PPARG (0.58) PPARGPPARAPPARDSIGMAR1RAB9A
SCHEMBL6488201 0.78 PPARG (0.74) PPARGPPARAPPARDRAB9AALDH1A1
SCHEMBL6484141 0.78 RAB9A (0.46) PPARGPPARAPPARDRAB9AALDH1A1
SCHEMBL6475653 0.77 L3MBTL1 (0.56) PPARGPPARAPPARDRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252150-B1 HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2003-06-04 EP claimed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US claimed
US-6919362-B2 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2005-07-19 US disclosed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same CYP2F1, CYP11B2, CYP4B1 PPARG 414/4885PPARA 845/4885PPARD 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.